Oramed Pharmaceuticals Inc. (ORMP) News

Oramed Pharmaceuticals Inc. (ORMP): $4.90

-0.51 (-9.43%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ORMP to Watchlist
Sign Up

Industry: Biotech


Ranked

of 396

in industry

Filter ORMP News Items

ORMP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ORMP News Highlights

  • ORMP's 30 day story count now stands at 2.
  • Over the past 1 day, the trend for ORMP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest ORMP News From Around the Web

Below are the latest news stories about Oramed Pharmaceuticals Inc that investors may wish to consider to help them evaluate ORMP as an investment opportunity.

ORMP: Moving Multiple Candidates & Studies Forward

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Oral COVID vaccine pill moving forward in several key international markets… Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) continues to advance its assets, and expand its management team and financial flexibility to support its growth initiatives. Oravax has secured pre-orders for Oravax’s COVID-19 oral vaccine, strengthened its cash position

Yahoo | February 23, 2022

We're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | February 22, 2022

Analysts Offer Insights on Healthcare Companies: Repare Therapeutics (RPTX), Oramed Pharmaceuticals (ORMP) and Citius Pharmaceuticals (CTXR)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repare Therapeutics (RPTX – Research Report), Oramed Pharmaceuticals (ORMP – Research Report) and Citius Pharmaceuticals (CTXR – Research Report) with bullish sentiments. Repare Therapeutics (RPTX) In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Repare Therapeutics, with a price target of $54.00. The company's shares closed last Friday at $15.23, close to its 52-week low of $13.97. According to TipRanks.

Brian Anderson on TipRanks | January 18, 2022

Oramed Issues Annual Message to Shareholders

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. To see a video message from the CEO please click here: https://www.youtube.com/watch?v=vgq1I7ylKsk

Yahoo | January 12, 2022

Oramed Pharmaceuticals Updates 1 Key Risk Factor

Shares of oral drug delivery systems, Oramed Pharmaceuticals, Inc. (ORMP) have gained 180.3% over the past year. OMRP is focused on developing solutions for the treatment of diabetes, with two pipeline candidates - ORMD-0801 and ORMD-0901. ORMD-0801 is being developed for treating diabetes and is currently under Phase-3 studies. Notably, ORMD-0801 can potentially become the first oral insulin capsule available commercially. Meanwhile, ORMD-0901 is targeted for type-2 diabetes. Moreover, Oravax Medical, wherein Oramed is the largest shareholder, recently entered into a cooperation and purchase agreement with Vietnam’s Tan Thanh Holdings. This agreement includes a 10 million dose pre-order of oral COVID-19 vaccines from Oravax (currently under development).

Kailas Salunkhe on TipRanks | January 6, 2022

Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the European Patent Office has granted the Company a patent titled "Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for Producing and Using Same." The patent supports Oramed's oral protein delivery platform technology which underlies its lead drug candidate ORMD-0801 now in pivot

Yahoo | January 5, 2022

H.C. Wainwright Remains a Buy on Oramed Pharmaceuticals (ORMP)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Oramed Pharmaceuticals (ORMP – Research Report), with a price target of $32.00. The company's shares closed last Wednesday at $13.10. According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of -18.5% and a 25.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals. Currently, the analyst consensus on Oramed Pharmaceuticals is a Strong Buy with an average price target of $34.25. See today’s best-performing stocks on TipRanks >> The company has a one-year high of $31.

Howard Kim on TipRanks | December 30, 2021

Oramed's Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh

Oramed Pharmaceuticals Inc. said Wednesday its Oravax Medical subsidiary has signed an agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Co. to pre-purchase 10 million doses of Oravax's oral COVID-19 vaccines in development. The drug maker's stock slipped 0.1% in premarket trading. The agreement is comprised of undisclosed milestone payments, and the companies have agreed to negotiate follow-on orders that could be worth "hundreds of millions of dollars." Tan Thanh has recei

Yahoo | December 29, 2021

Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that its subsidiary, Oravax Medical, has signed a Cooperation and Purchase Agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Company to pre-purchase Oravax's oral COVID-19 vaccine, currently in development. The agreement grants Tan Thanh Holdings the right to sell Oravax's oral vaccine in

Yahoo | December 29, 2021

Israel's Oramed gets Vietnam pre-order for 10 mln COVID-19 vaccine doses

Israel's Oramed Pharmaceuticals said on Wednesday its Oravax Medical unit signed a deal with Vietnam's Tan Thanh Holdings for the pre-order of 10 million doses of its oral COVID-19 vaccine that is in clinical trials. The agreement gives Tan Thanh, a drug distributor, the right to sell Oravax’s oral vaccine in development throughout the Association of Southeast Asian Nations (ASEAN), which includes Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam, Oramed said.

Yahoo | December 29, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4609 seconds.